🔗 Share this article

While the United States continues making historic adjustments to its immunization schedules, one figure has surfaced unexpectedly: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots during the global health crisis and has concentrated on possible fatalities following COVID-19 immunization in her short position at the FDA.

Proposed Overhauls to Childhood Vaccine Program

Health officials planned to reveal major changes to the childhood vaccination calendar in December, bringing the US with Denmark’s immunization schedule, according to reports – a significant shift that would put the US at odds with much of the international standard with little proof for benefit. This reveal has been pushed back until the coming year.

Instead of the director of the vaccine center, Høeg is set to present at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the office this calendar year.

A New Direction at the FDA

Høeg's temporary position may indicate a closer partnership between the drug and biologics centers as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a increased emphasis upon rolling back long-standing immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific pediatric vaccine recommendations in the US so as to align more similar to the Danish model, a society with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – typically the domain of Dr. Prasad, director of the FDA’s CBER – as opposed to medication approval.

Concerns Over Qualifications

The appointee has no apparent background in pharmaceutical research, regulation or management, which has been standard for past directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and the vaccine center since March.

“It seems she lacks to have the necessary background” for running the drug-regulation department, stated Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in leading a large organization. She is not an expert in drug approvals.”

Former commissioners of the center would “be deeply familiar with laws and regulations and the research of medication creation”, commented a former acting FDA commissioner. “Objectively, she has not acquired the type of experience that prior appointees who led the center have had.”

This division has an immense workload at the agency, Woodcock stated.

“The public just zeroes in on the innovative therapies, but the generic drug division approves a multitude of generic drugs. There is also a biosimilars division, OTC medication office and so forth, and every single one need to be managed,” she noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership aspect to the role, which supervises more than 5,000 employees. “It is a massive administrative position, if you do it right,” Woodcock concluded.

Official Statement and Controversial Initiatives

In response to inquiries about Dr. Høeg's fitness for the role and whether this appointment indicates greater collaboration among agency officials on vaccines, a spokesperson said that the “questions stem from flawed assumptions”.

“Her experience aligns with the responsibilities of her position,” the official stated, noting the time Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

As the temporary head, Dr. Høeg assumes responsibility for the agency head's recently launched expedited review system, a disputed expedited medication authorization process that allegedly troubled her former heads. “How are these therapies being picked for this expedited pathway? Who makes the decisions?” Howard questioned. “There is a lot of lack of transparency happening at the FDA right now.”

Broadly speaking, he remarked, “the Food and Drug Administration seems to be moving towards less stringent rules of pharmaceuticals, aside from vaccines.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a more documented, if concerning, history, critics have noted. She authored a study using unconfirmed public submissions to assess the frequency of myocarditis following Covid vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have changed statistics to imply COVID-19 vaccinations are more dangerous than they are.

Part of her “wish list” for the incoming federal leadership encompassed altering guidelines for recently developed shots and discontinuing “non-essential” vaccines, she remarked following the vote on a online show. At the FDA, Dr. Høeg has according to sources floated the idea of preventing young men from obtaining COVID-19 vaccines.

“She is an all-around dogmatist who commences with her beliefs and tailors the evidence to fit the science in a highly deceptive, fraudulent manner,” Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg joined other contrarians, {like|